COVID-19 Funding Opportunities
The Office of the Vice Provost for Research (VPR) has compiled a list of funding opportunities specific to COVID-19. This list will be updated as new opportunities arise.
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use. If no award is given by mid-2018,
The Michael J. Fox Foundation will evaluate the state of the field and
utility of such a prize.